P021 Melanoma
DESCRIPTION
Our understanding of melanoma biology, risk, and diagnosis continues to evolve rapidly. This session will cover topics ranging from the potential roles and innovation opportunities presented by melanoma public health, diagnostic technologies, and innovative surgical and medical approaches to melanoma.
LEARNING OBJECTIVES
Describe the latest technologies available for the diagnosis of melanoma.
Recognize innovative techniques for public health in melanoma.
Critically evaluate innovative surgical and medical oncology approaches to melanoma.
SCHEDULE
8:00 PM
Welcome & Introductions
Sancy A Leachman, MD, PhD, FAAD
8:10 PM
War on Melanoma: Innovations in public health
Sancy A Leachman, MD, PhD, FAAD
8:20 PM
Innovation updates in dermoscopy & RCM
Joanna Ludzik, MD, PhD, IFAAD
8:40 PM
Digital pathology & diagnosis of melanoma
Stephanie Mengden, MD, FAAD
9:00 PM
Panel Discussion
9:15 PM
How dangerous are melanoma mobile apps?
Ravi Samatham
9:35 PM
Teledermoscopy & AI-driven clinical support
Alexander Witkowski, MD, PhD
9:55 PM
Is it time to use Mohs for melanoma?
Olivia Marie Lucero, MD, FAAD
10:15 PM
Next Generation Therapies for Melanoma
Matthew Blackburn
10:35 PM
When and why should you refer to a oncodermatologist?
Noah Io Hornick, MD, PhD, FAAD
10:45 PM
Panel Discussion
SPEAKERS
Matthew Blackburn
Noah Io Hornick, MD, PhD, FAAD
Oregon Health & Science University
Sancy A Leachman, MD, PhD, FAAD
Oregon Health & Science University
Olivia Marie Lucero, MD, FAAD
Joanna Ludzik, MD, PhD, IFAAD
Stephanie Mengden, MD, FAAD
Ravi Samatham
Alexander Witkowski, MD, PhD
Oregon Health and Science University
HANDOUTS
SPEAKER DISCLOSURES
Matthew Blackburn
No financial relationships exist with ineligible companies.
Noah Io Hornick, MD, PhD, FAAD
Shook Hardy & Bacon – Consultant (1099 relationship)(Fees); Therakos, Inc. – Data Safety Monitoring Board(Fees);
Sancy A Leachman, MD, PhD, FAAD
Castle Biosciences, Inc – Investigator(No Compensation Received); Epi-Q – Consultant (1099 relationship)(Honoraria); Merck & Co., Inc – Advisory Board(Honoraria); OrLucent, Inc. – Advisory Board(Honoraria); Pathology Watch – Advisory Board(No Compensation Received), Investigator(Grants/Research Funding); Sklip Inc. – Investigator(No Compensation Received); Veriskin – Advisory Board(No Compensation Received), Investigator(No Compensation Received);
Olivia Marie Lucero, MD, FAAD
No financial relationships exist with ineligible companies.
Joanna Ludzik, MD, PhD, IFAAD
No financial relationships exist with ineligible companies.
Stephanie Mengden, MD, FAAD
No financial relationships exist with ineligible companies.
Ravi Samatham
No financial relationships exist with ineligible companies.
Alexander Witkowski, MD, PhD
No financial relationships exist with ineligible companies.